TITLE

Coadministration of Adenoviral Vascular Endothelial Growth Factor and Angiopoietin-1 Enhances Vascularization and Reduces Ventricular Remodeling in the Infarcted Myocardium of Type 1 Diabetic Rats

AUTHOR(S)
Samuel, Samson Mathews; Akita, Yuzo; Paul, Debayon; Thirunavukkarasu, Mahesh; Zhan, Lijun; Sudhakaran, Perumana R.; Li, Chuanfu; Maulik, Nilanjana
PUB. DATE
January 2010
SOURCE
Diabetes;Jan2010, Vol. 59 Issue 1, p51
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE--Hyperglycemia impairs angiogenesis in response to ischemia, leading to ventricular remodeling. Although the effects of overexpressing angiogenic growth factors have been studied in inducing angiogenesis, the formation of functional vessels remains a challenge. The present study evaluates the reversal of diabetes-mediated impairment of angiogenesis in the infarcted diabetic rat myocardium by proangiogenic gene therapy. RESEARCH DESIGN AND METHODS--Ad.VEGF and Ad.Ang1 were intramyocardially administered in combination immediately after myocardial infarction to nondiabetic and diabetic rats. Ad.LacZ was similarly administered to the respective control groups. The hearts were excised for molecular and immunohistochemical analysis at predetermined time points. The myocardial function was measured by echocardiography 30 days after the intervention. RESULTS--We observed reduced fibrosis and increased capillary/arteriolar density along with reduced ventricular remodeling, as assessed by echocardiography in the treated diabetic animals compared with the nontreated diabetic controls. We also observed increased phosphorylated mitogen-activated protein kinase-activated protein kinase-2, 2 days after the treatment and increased expression of vascular endothelial growth factor (VEGF), Flk-1, angiopoietin-1 (Ang-1), Tie-2, and survivin, 4 days after treatment in the diabetic animals. Gel shift analysis revealed that the combination gene therapy stimulated the DNA binding activity of nuclear factor-κB in the diabetic animals. CONCLUSIONS--Our preclinical data demonstrate the efficacy of coadministration of adenoviral VEGF and Ang-1 in increasing angiogenesis and reducing ventricular remodeling in the infarcted diabetic myocardium. These unique results call for the initiation of a clinical trial to assess the efficacy of this therapeutic strategy in the treatment of diabetes-related human heart failure. Diabetes 59:51-60, 2010
ACCESSION #
47995249

 

Related Articles

  • Stimulating Functional Blood Vessel Growth. Breindl, Anette // BioWorld Today;3/26/2012, Vol. 23 Issue 58, Special section p1 

    The article reports on a study which successfully stimulated therapeutic angiogenesis or blood vessel growth by gene therapy that delivered vascular endothelial growth factor (VEGF) and platelet-derived growth factor-BB or PDGF-BB, to cells in fixed ratios.

  • Adeno-associated viral vector-mediated human vascular endothelial growth factor gene transfer stimulates angiogenesis and wound healing in the genetically diabetic mouse M. Galeano et al.: VEGF gene therapy in diabetic wound healing. Galeano, M.; Deodato, B.; Altavilla, D.; Cucinotta, D.; Arsic, N.; Marini, H.; Torre, V.; Giacca, M.; Squadrito, F. // Diabetologia;Apr2003, Vol. 46 Issue 4, p546 

    Aims/hypothesis. We studied the gene therapy efficacy of diabetes-associated wound healing disorder with an adeno-associated virus (AAV) vector expressing the 165-amino acid isoform of human vascular endothelial growth factor-A (VEGF-A) by using an incisional skin-wound model produced on the...

  • Diabetic Retinopathy and Angiogenesis. Crawford, Talia N.; Alfaro III, D. Virgil; Kerrison, John B.; Jablon, Eric P. // Current Diabetes Reviews;2009, Vol. 5 Issue 1, p8 

    Diabetic retinopathy, a secondary microvascular complication of diabetes mellitus is the leading cause of blindness in the Unites States amongst individuals age 20 to 64. Two major retinal problems cause most of the diabetes-related vision loss: diabetic macular edema and complications from...

  • Getting a Notch Closer to Understanding Diabetic Kidney Disease. Ahn, Seon-Ho; Susztak, Katalin // Diabetes;Aug2010, Vol. 59 Issue 8, p1865 

    The authors examine a study on the interaction of the Notch and vascular endothelial growth factor (VEGF) pathways in diabetic podocytes and their role in the development of diabetic kidney disease (DKD). The study shows that the activation of Notch signaling in cultured human podocytes is...

  • PKC Inhibition and Diabetic Complications. Nogueira-Machado, Jos� A.; Bosco, Adriana A. // Recent Patents on Endocrine, Metabolic & Immune Drug Discovery;Jun2008, Vol. 2 Issue 2, p72 

    Hyperglycemia activates several signaling pathways associated with vascular complications in diabetes. Hyperfunction of the diacylglycerol - protein kinase C (DAG-PKC) pathway can lead to enhanced vascular permeability, endothelial cell activation and expression of leukocyte adhesion molecules,...

  • A Critical Role for Thioredoxin-Interacting Protein in Diabetes-Related Impairment of Angiogenesis. Dunn, Louise L.; Simpson, Philippa J. L.; Prosser, Hamish C.; Lecce, Laura; Yuen, Gloria S. C.; Buckle, Andrew; Sieveking, Daniel P.; Vanags, Laura Z.; R. Lim, Patrick; Chow, Renee W. Y.; Lam, Yuen Ting; Clayton, Zoe; Bao, Shisan; Davies, Michael J.; Stadler, Nadina; Celermajer, David S.; Stocker, Roland; Bursill, Christina A.; Cooke, John P.; Ng, Martin K. C. // Diabetes;Feb2014, Vol. 63 Issue 2, p675 

    Impaired angiogenesis in ischemic tissue is a hallmark of diabetes. Thioredoxin-interacting protein (TXNIP) is an exquisitely glucose-sensitive gene that is overexpressed in diabetes. As TXNIP modulates the activity of the key angiogenic cytokine vascular endothelial growth factor (VEGF), we...

  • Current Status of Cardiovascular Gene Therapy. Rissanen, Tuomas T.; Ylä-Herttuala, Seppo // Molecular Therapy;Jul2007, Vol. 15 Issue 7, p1233 

    Gene transfer for the therapeutic modulation of cardiovascular diseases is an expanding area of gene therapy. During the last decade several approaches have been designed for the treatment of hyperlipidemias, post-angioplasty restenosis, hypertension, and heart failure, and for protection of...

  • Cell and Gene Therapy Approaches for Cardiac Vascularization. Melly, Ludovic; Boccardo, Stefano; Eckstein, Friedrich; Banfi, Andrea; Marsano, Anna // Cells (2073-4409);Dec2012, Vol. 1 Issue 4, p961 

    Despite encouraging preclinical results for therapeutic angiogenesis in ischemia, a suitable approach providing sustained, safe and efficacious vascular growth in the heart is still lacking. Vascular Endothelial Growth Factor (VEGF) is the master regulator of angiogenesis, but it also can easily...

  • Downregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer. Xiaolong Zou; Haiquan Qiao; Xian Jiang; Xuesong Dong; Hongchi Jiang; Xueying Sun // Journal of Biomedical Science;2009, Vol. 16, p1 

    Developmentally regulated endothelial cell locus-1 (Del1) is an embryonic angiogenic factor expressed in early embryonic endothelial cells, but recently has been found to be expressed in some forms of cancers including colon and breast cancers, and melanoma, and human cancer cell lines....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics